Richa Poddar
Net worth: 439 548 $ as of 2024-04-29
Profile
Richa Poddar worked as the Chief Commercial Officer at Agios Pharmaceuticals, Inc. from 2021 to 2022.
Prior to that, she worked as the Head of Marketing at Clovis Oncology, Inc. She holds a graduate degree from Keck Graduate Institute of Applied Life Sciences and an undergraduate degree from the University of Pune.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2023-03-30 | 13,879 ( 0.02% ) | 439 548 $ | 2024-04-29 |
Former positions of Richa Poddar
| Companies | Position | End |
|---|---|---|
| AGIOS PHARMACEUTICALS, INC. | Corporate Officer/Principal | 2022-12-30 |
| CLOVIS ONCOLOGY, INC. | Sales & Marketing | - |
Training of Richa Poddar
| University of Pune | Undergraduate Degree |
| Keck Graduate Institute of Applied Life Sciences | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| AGIOS PHARMACEUTICALS, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Clovis Oncology, Inc.
 Clovis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional international markets. Its U.S. marketed product, Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is approved for use in the maintenance treatment and treatment of eligible adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer, and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC), which have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. In Europe, Rubraca is approved for use in recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO. | Health Technology |
- Stock Market
- Insiders
- Richa Poddar